Melo Gustavo Barreto, Ferreira Magno, Maia Maurício
Hospital de Olhos de Sergipe, Aracaju, SE, Brazil.
Universidade Federal de São Paulo, São Paulo, SP, Brazil.
Arq Bras Oftalmol. 2020 Jun;83(3):175-179. doi: 10.5935/0004-2749.20200031. Epub 2020 Feb 10.
This survey aimed at assessing the clinical characteristics of patients with inflammatory reactions after intravitreal injection of antiangiogenic agents and the techniques employed by Brazilian retina specialists.
We sent an 18-item questionnaire electronically to retina specialists who are using antiangiogenic agents. We got the responses between September 21 and December 23, 2018.
A total of 58 retina specialists participated. Most of them were from Southeastern Brazil (50%), 82.8% were dedicated to both medical and surgical practices, and 86.2% had practiced for more than 5 years. Respondents reported a mean number of 2.14 ± 1.63 patients with inflammation, 44.8% with panuveitis, and 79.3% with onset of symptoms within 72 h. Specialists used aflibercept (53.4%), bevacizumab (29.3%), and ranibizumab (27.6%). Most patients were treated with steroid drops (70.7%), and their inflammation subsided after 11.5 ± 11.5 days (86.2% lacked irreversible complications). The specialists blamed the syringe as the cause of the inflammation in 25.9% of the cases, 41.4% used Becton-Dickinson Ultra-Fine syringes, 43.1% injected the drug at room temperature, and 37.9% removed the air (53.4% by flicking the syringe). Most specialists did not detect silicone oil (67.2%), but 17.2% of them performed vitrectomies to remove vitreous opacities. Finally, 44.8% of specialists injected the same antiangiogenic agent in an eye with prior inflammatory reaction without further inflammation.
Most specialists reported cases of early-onset inflammation after intravitreal injection of antiangiogenic agents. The incidence of irreversible complications was low. Aflibercept was the most common agent used. The causes of inflammation remain unknown, but we formulated some relevant hypotheses.
本调查旨在评估玻璃体内注射抗血管生成药物后发生炎症反应患者的临床特征以及巴西视网膜专家所采用的技术。
我们以电子方式向正在使用抗血管生成药物的视网膜专家发送了一份包含18个条目的问卷。我们在2018年9月21日至12月23日期间收到了回复。
共有58名视网膜专家参与。他们中的大多数来自巴西东南部（50%），82.8%既从事医疗实践也从事手术操作，86.2%的从业时间超过5年。受访者报告炎症患者的平均数量为2.14±1.63例，44.8%患有全葡萄膜炎，79.3%在72小时内出现症状。专家们使用阿柏西普（53.4%）、贝伐单抗（29.3%）和雷珠单抗（27.
